JP2019518063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518063A5 JP2019518063A5 JP2018566377A JP2018566377A JP2019518063A5 JP 2019518063 A5 JP2019518063 A5 JP 2019518063A5 JP 2018566377 A JP2018566377 A JP 2018566377A JP 2018566377 A JP2018566377 A JP 2018566377A JP 2019518063 A5 JP2019518063 A5 JP 2019518063A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- hetaryl
- heterocyclyl
- cycloalkyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims description 185
- 125000000623 heterocyclic group Chemical group 0.000 claims description 161
- 125000003118 aryl group Chemical group 0.000 claims description 159
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 121
- 125000000304 alkynyl group Chemical group 0.000 claims description 114
- 125000000217 alkyl group Chemical group 0.000 claims description 109
- 125000003342 alkenyl group Chemical group 0.000 claims description 81
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 239000012824 ERK inhibitor Substances 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 230000003321 amplification Effects 0.000 claims description 16
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 230000002018 overexpression Effects 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102100022992 Anoctamin-1 Human genes 0.000 claims description 8
- 108010058546 Cyclin D1 Proteins 0.000 claims description 8
- 102000006311 Cyclin D1 Human genes 0.000 claims description 8
- 101000757261 Homo sapiens Anoctamin-1 Proteins 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 230000009286 beneficial effect Effects 0.000 claims description 6
- 210000000349 chromosome Anatomy 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- RZUOCXOYPYGSKL-GOSISDBHSA-N 1-[(1s)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]pyridin-2-one Chemical compound CN1N=CC=C1NC1=NC=CC(C2=CC(=O)N([C@H](CO)C=3C=C(F)C(Cl)=CC=3)C=C2)=N1 RZUOCXOYPYGSKL-GOSISDBHSA-N 0.000 claims description 4
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims description 4
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 claims description 4
- KPQQGHGDBBJGFA-QNGWXLTQSA-N MK-8353 Chemical compound C([C@@](C1)(SC)C(=O)NC=2C=C3C(C=4C=NC(OC(C)C)=CC=4)=NNC3=CC=2)CN1CC(=O)N(CC=1)CCC=1C(C=C1)=CC=C1C=1N=CN(C)N=1 KPQQGHGDBBJGFA-QNGWXLTQSA-N 0.000 claims description 4
- 238000011529 RT qPCR Methods 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 230000000052 comparative effect Effects 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 238000003364 immunohistochemistry Methods 0.000 claims description 4
- 238000007834 ligase chain reaction Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000003752 polymerase chain reaction Methods 0.000 claims description 4
- 238000003753 real-time PCR Methods 0.000 claims description 4
- 239000000523 sample Substances 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- XVECMUKVOMUNLE-UHFFFAOYSA-N 5-(2-phenyl-3-pyrazolo[1,5-a]pyridinyl)-2H-pyrazolo[3,4-c]pyridazin-3-amine Chemical compound C1=C2C(N)=NNC2=NN=C1C(=C1C=CC=CN1N=1)C=1C1=CC=CC=C1 XVECMUKVOMUNLE-UHFFFAOYSA-N 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 claims description 2
- ODIUJYZERXVGEI-UHFFFAOYSA-N 6-benzyl-3-pyridin-4-yl-5,8-dihydro-1H-pyrazolo[4,3-g]quinazolin-7-one Chemical compound O=C1Nc2cc3[nH]nc(-c4ccncc4)c3cc2CN1Cc1ccccc1 ODIUJYZERXVGEI-UHFFFAOYSA-N 0.000 claims description 2
- 206010005081 Bladder squamous cell carcinoma stage unspecified Diseases 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 102100026693 FAS-associated death domain protein Human genes 0.000 claims description 2
- -1 GDC-0094 Chemical compound 0.000 claims description 2
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 claims description 2
- 101001020310 Homo sapiens Liprin-alpha-1 Proteins 0.000 claims description 2
- 101000619488 Homo sapiens Protein LTO1 homolog Proteins 0.000 claims description 2
- 101000829367 Homo sapiens Src substrate cortactin Proteins 0.000 claims description 2
- 102100035684 Liprin-alpha-1 Human genes 0.000 claims description 2
- PWHIUQBBGPGFFV-GOSISDBHSA-N N-[(1S)-2-amino-1-(3-chloro-5-fluorophenyl)ethyl]-1-[5-methyl-2-(oxan-4-ylamino)pyrimidin-4-yl]imidazole-4-carboxamide Chemical compound NC[C@H](C1=CC(=CC(=C1)F)Cl)NC(=O)C=1N=CN(C=1)C1=NC(=NC=C1C)NC1CCOCC1 PWHIUQBBGPGFFV-GOSISDBHSA-N 0.000 claims description 2
- 102100022152 Protein LTO1 homolog Human genes 0.000 claims description 2
- HDAJDNHIBCDLQF-RUZDIDTESA-N SCH772984 Chemical compound O=C([C@@H]1CCN(C1)CC(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1N=CC=CN=1)NC(C=C12)=CC=C1NN=C2C1=CC=NC=C1 HDAJDNHIBCDLQF-RUZDIDTESA-N 0.000 claims description 2
- 102100030680 SH3 and multiple ankyrin repeat domains protein 2 Human genes 0.000 claims description 2
- 101710067890 SHANK2 Proteins 0.000 claims description 2
- 238000002105 Southern blotting Methods 0.000 claims description 2
- 208000034331 Squamous cell carcinoma of the stomach Diseases 0.000 claims description 2
- 102100023719 Src substrate cortactin Human genes 0.000 claims description 2
- BQNGEEDNZRILLS-HZLVCURZSA-N [(1r,5r,6r,7s)-6-methyl-1,3,7-tris(3-methylbut-2-enyl)-6-(4-methylpent-3-enyl)-5-(2-methylpropanoyl)-4,9-dioxo-2-bicyclo[3.3.1]non-2-enyl] 3,4,5-trimethoxybenzoate Chemical compound COC1=C(OC)C(OC)=CC(C(=O)OC=2[C@]3(CC=C(C)C)C(=O)[C@]([C@]([C@@H](CC=C(C)C)C3)(C)CCC=C(C)C)(C(=O)C(C)C)C(=O)C=2CC=C(C)C)=C1 BQNGEEDNZRILLS-HZLVCURZSA-N 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 201000006598 bladder squamous cell carcinoma Diseases 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- SALVHVNECODMJP-GNUCVDFRSA-N diazepinomicin Chemical compound O=C1N(C/C=C(C)/CC/C=C(C)/CCC=C(C)C)C2=CC(O)=CC(O)=C2NC2=C(O)C=CC=C21 SALVHVNECODMJP-GNUCVDFRSA-N 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 201000000496 gastric squamous cell carcinoma Diseases 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 201000003911 head and neck carcinoma Diseases 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 238000002493 microarray Methods 0.000 claims description 2
- KSERXGMCDHOLSS-LJQANCHMSA-N n-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)=C1Cl KSERXGMCDHOLSS-LJQANCHMSA-N 0.000 claims description 2
- ILUKRINUNLAVMH-UHFFFAOYSA-N n-[2-[[2-[(2-methoxy-5-methylpyridin-4-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]-5-methylphenyl]prop-2-enamide Chemical compound C1=NC(OC)=CC(NC=2N=C(NC=3C(=CC(C)=CC=3)NC(=O)C=C)C(=CN=2)C(F)(F)F)=C1C ILUKRINUNLAVMH-UHFFFAOYSA-N 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 238000010839 reverse transcription Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 0 *[*+]1N=C(*)c(cc2CN3*)c1cc2NC3=O Chemical compound *[*+]1N=C(*)c(cc2CN3*)c1cc2NC3=O 0.000 description 4
- FTYFEXZBNYBQEY-UHFFFAOYSA-N CCNC(Nc(cc1)nc2c1ncc(-c1c[n](CC(C)C)nc1)n2)=O Chemical compound CCNC(Nc(cc1)nc2c1ncc(-c1c[n](CC(C)C)nc1)n2)=O FTYFEXZBNYBQEY-UHFFFAOYSA-N 0.000 description 1
- WUTVMXLIGHTZJC-UHFFFAOYSA-N Cc1c(-c2c[nH]c(C(NC(CO)c3cccc(Cl)c3)=O)c2)nc(Nc(c(Cl)c2)ccc2F)nc1 Chemical compound Cc1c(-c2c[nH]c(C(NC(CO)c3cccc(Cl)c3)=O)c2)nc(Nc(c(Cl)c2)ccc2F)nc1 WUTVMXLIGHTZJC-UHFFFAOYSA-N 0.000 description 1
- AIMJWAQVOUDRCO-ZSOIEALJSA-N NCCCCC(C(/C(/S1)=C/c(cc2)cc3c2OCO3)=O)C1=O Chemical compound NCCCCC(C(/C(/S1)=C/c(cc2)cc3c2OCO3)=O)C1=O AIMJWAQVOUDRCO-ZSOIEALJSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352533P | 2016-06-20 | 2016-06-20 | |
| US62/352,533 | 2016-06-20 | ||
| US201662428379P | 2016-11-30 | 2016-11-30 | |
| US62/428,379 | 2016-11-30 | ||
| US201762502996P | 2017-05-08 | 2017-05-08 | |
| US62/502,996 | 2017-05-08 | ||
| PCT/US2017/038084 WO2017222958A1 (en) | 2016-06-20 | 2017-06-19 | Treatment of squamous cell carcinomas with inhibitors of erk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518063A JP2019518063A (ja) | 2019-06-27 |
| JP2019518063A5 true JP2019518063A5 (cg-RX-API-DMAC7.html) | 2020-07-16 |
Family
ID=60783255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566377A Pending JP2019518063A (ja) | 2016-06-20 | 2017-06-19 | Ｅｒｋ阻害剤を用いた扁平上皮細胞癌の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190192517A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3471717A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019518063A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109661228A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201805000A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017222958A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3307727T3 (pl) | 2015-06-15 | 2024-07-08 | Asana Biosciences, Llc | Heterocykliczne inhibitory erk1 i erk2 oraz ich zastosowanie w leczeniu nowotworów |
| CN117530948A (zh) | 2016-12-05 | 2024-02-09 | G1治疗公司 | 化疗方案期间免疫反应的保持 |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| EP3699179A4 (en) * | 2017-10-19 | 2021-06-16 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | TRICYCLIC DERIVATIVE CONTAINING PYRAZOLYL, PROCESS FOR PREPARATION AND USE |
| CN111821434A (zh) * | 2019-04-17 | 2020-10-27 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 |
| FI3853234T3 (fi) | 2018-09-18 | 2025-07-28 | Nikang Therapeutics Inc | Fuusioituja trisyklisiä rengasjohdannaisia SRC-homologia-2-fosfataasin estäjinä |
| WO2020200161A1 (zh) * | 2019-04-02 | 2020-10-08 | 上海翰森生物医药科技有限公司 | 含吲唑基的三并环类衍生物的盐及其晶型 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| AU2022257020A1 (en) * | 2021-04-16 | 2023-11-30 | Erasca, Inc. | Uses of heterocyclic inhibitors of erk1/2 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7151161B1 (en) * | 1998-01-13 | 2006-12-19 | Oscient Pharmaceuticals Corporation | Human genes of chromosome 11q13.3 |
| PE20051128A1 (es) * | 2004-02-25 | 2006-01-16 | Schering Corp | Pirazolotriazinas como inhibidores de quinasa |
| JP2006094733A (ja) * | 2004-09-28 | 2006-04-13 | As One Corp | 癌の検出方法 |
| AU2007223311C1 (en) * | 2006-03-02 | 2013-06-20 | The Board Of Regents Of The University Of Oklahoma | MicroRNA expression profile associated with pancreatic cancer |
| WO2013106812A1 (en) * | 2012-01-12 | 2013-07-18 | Board Of Regents, The University Of Texas System | Personalized medicine for the prediction of therapy targeting the hedgehog pathway |
| KR20160081908A (ko) * | 2013-10-03 | 2016-07-08 | 쿠라 온콜로지, 인크. | Erk의 억제제 및 사용 방법 |
-
2017
- 2017-06-19 WO PCT/US2017/038084 patent/WO2017222958A1/en not_active Ceased
- 2017-06-19 JP JP2018566377A patent/JP2019518063A/ja active Pending
- 2017-06-19 EP EP17815990.1A patent/EP3471717A4/en not_active Withdrawn
- 2017-06-19 CN CN201780051014.8A patent/CN109661228A/zh active Pending
- 2017-06-19 TW TW106120308A patent/TW201805000A/zh unknown
-
2018
- 2018-12-17 US US16/222,398 patent/US20190192517A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518063A5 (cg-RX-API-DMAC7.html) | ||
| JP5690588B2 (ja) | 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法 | |
| AU2009240021B2 (en) | Antiviral therapy | |
| JP2011529691A5 (cg-RX-API-DMAC7.html) | ||
| JP2012526554A5 (cg-RX-API-DMAC7.html) | ||
| US20120264626A1 (en) | MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof | |
| CN103608683A (zh) | Hedgehog抑制剂治疗的生物标志物 | |
| US9890428B2 (en) | MiRNA biomarkers for radiation biodosimetry | |
| US20140134158A1 (en) | Kras mutations and resistance to anti-egfr treatment | |
| US20100167302A1 (en) | Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy | |
| JP2017536357A (ja) | Ｉｌ−３３媒介性障害のための治療及び診断方法 | |
| CN103402517A (zh) | 使用braf抑制剂的治疗方法 | |
| WO2012094394A2 (en) | Methods and compositions for assessing and treating adrenal diseases and disorders | |
| JP2015530868A5 (cg-RX-API-DMAC7.html) | ||
| KR20160057416A (ko) | 식도암에 대한 분자적 진단 검사 | |
| Zhang et al. | Serum miR-483-5p as a potential biomarker to detect hepatocellular carcinoma | |
| JP2018527886A5 (cg-RX-API-DMAC7.html) | ||
| Pinto et al. | Functional annotation of proteome encoded by human chromosome 22 | |
| US20210348238A1 (en) | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy | |
| JP6348699B2 (ja) | インターフェロン治療効果予測方法 | |
| Ghaderzadeh et al. | Transcriptomic and biometric parameters analysis in rainbow trout (Oncorhynchus mykiss) challenged with viral hemorrhagic septicemia virus (VHSV) | |
| US11952631B2 (en) | Diagnostics and therapy for human respiratory syncytial virus | |
| CN109937260A (zh) | 提供流感感染预后的组合物和方法 | |
| Scelo et al. | Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer | |
| WO2025221816A1 (en) | Method and system of using biomarkers for xenograft damage or rejection |